## Cidofovir

| Spectrum of Activity* | CMV  
Herpesvirus (HSV, VZV)  
JC virus |
|----------------------|--------------------------------------------------|
| **Indications**      | An option for UL97-mutant ganciclovir resistant CMV  
Potentially acyclovir resistant HSV  
Clinical efficacy has been demonstrated only for CMV. Its clinical utility in infections caused by other viral pathogens remains to be determined |
| **Not indicated**    | |
| **Safety Considerations** | Administered weekly  
High risk of nephrotoxicity (Fanconi-like syndrome): proteinuria, glycosuria, polyuria, acidosis, phosphaturia.  
Nausea, fever, alopecia, myalgias, neutropenia, iritis/uveitis.  
Prehydration with 1L of normal saline before infusion and, if tolerable, another 1L during or following the infusion.  
Probenecid 2 g PO 3h prior and 1 g PO 2h and 8h following each cidofovir infusion |
| **Renal Dosing**     | Contraindicated if CrCl ≤ 55 mL/min or concomitant nephrotoxic agents or proteinuria (2+ or greater) |
| **Other Considerations** | Close serum creatinine and urine protein monitoring (prior to each dose) with early dose adjustment for kidney injury:  
- dose reduce for increase of 25-35 µmol/L in serum creatinine  
- stop if proteinuria (2-3+ or greater) or increase of 44µmol/L above baseline creatinine |